AMD

RetroSense Therapeutics Announces Notice of Allowance for New U.S. Patent Application Broadly Covering Optogenetic Approaches to Vision Restoration

RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12/299,574), which broadly covers methods of restoring visual responses with a variety of optogenetic compounds.